Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial

Overview of attention for article published in The Lancet Haematology, November 2022

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
Among the highest-scoring outputs from this source (#20 of 1,291)
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (97th percentile)

So far, Altmetric has seen 39 news stories from 39 outlets.

Kathryn Maples, PharmD, BCOP, highlights recent approvals, and updated labeling, along with drug removals, across leukemia…

Early clinical data support olutasidenib's potential as a treatment for AML and MDS, in both the relapsed/refractory and newly…

Early clinical data support olutasidenib's potential as a treatment for AML and MDS, in both the relapsed/refractory and newly…

Please enter a search term. Please enter a search term. News provided by Nov 10, 2022, 4:05 PM ET SOUTH SAN FRANCISCO, Calif.…

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity, including 35 additional news stories.